help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2006-0964
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nimkarn, S.
Right arrow Articles by New, M. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nimkarn, S.
Right arrow Articles by New, M. I.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
*Genetics Home Reference
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Pediatric Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 1 137-142
Copyright © 2007 by The Endocrine Society

Aldosterone-to-Renin Ratio as a Marker for Disease Severity in 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

Saroj Nimkarn, Karen Lin-Su, Niklas Berglind, Robert C. Wilson and Maria I. New

Department of Pediatrics (S.N., K.L.-S., R.C.W., M.I.N.), Adrenal Steroid Disorders Program, and Department of Community and Preventive Medicine (N.B.), Mount Sinai School of Medicine, New York, New York 10029

Address all correspondence and requests for reprints to: Maria I. New, M.D., Director, Division of Adrenal Steroid Disorders, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1198, New York, New York 10029. E-mail: maria.new{at}mssm.edu.

Context: Congenital adrenal hyperplasia (CAH) owing to 21-hydroxylase deficiency (21 OHD) is classified clinically in decreasing order of severity into salt-wasting, simple-virilizing, and nonclassical forms. Causative mutations in the CYP21A2 gene dictate the degrees of adrenal enzyme defect. Salt-wasting crises due to aldosterone deficiency are clinically apparent in the salt-wasting form but not in other forms of 21 OHD.

Objectives: This study examined the ratio of serum aldosterone to plasma renin activity as an index of sodium wasting in patients with 21 OHD CAH, heterozygotes, and normal individuals.

Design: This was a cross-sectional, retrospective, noninterventional study.

Patients and Other Participants: A total of 402 individuals were included: 224 patients affected with 21 OHD CAH and 178 unaffected subjects. Classification into each diagnostic group was made primarily on the basis of clinical and hormonal features. Affected or unaffected status was confirmed by genotype of CYP21A2. All subjects were on ad lib diets without restrictions. Salt-wasting status was examined by sodium deprivation testing in 32 salt-wasting subjects and 14 simple virilizing subjects.

Results: The ratio of serum aldosterone to plasma renin activity was found to discriminate well between the different groups of disease severity. The lowest ratios, indicative of the least sodium conservation, were seen in the salt-wasting group with increasing ratios in the simple virilizing, nonclassical, and unaffected groups. This ratio remained stable with age.

Conclusion: The ratio of serum aldosterone to plasma renin activity provides a simple index to compare groups of patients with varying degrees of 21 OHD.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society